Core Viewpoint - The statement from Aikang Group addresses a complaint from a client, Ms. Zhang, regarding the accuracy of her health check results over a ten-year period, highlighting the complexities of cancer detection and the limitations of current diagnostic methods [1] Group 1: Company Response - Aikang Group released a statement on July 17, responding to media reports about Ms. Zhang's cancer diagnosis after ten years of normal test results [1] - The company emphasizes that cancer development is a gradual process influenced by various factors, including the timing of tests, detection methods, and the expertise of medical professionals [1] - Aikang Group plans to collaborate with a third-party authority and experts to analyze the situation and will accept responsibility if found at fault [1] Group 2: Industry Context - According to the 2022 edition of the "Guidelines for Diagnosis and Treatment of Renal Cell Carcinoma" published by the People's Medical Publishing House, there are currently no recognized serum tumor markers for the early auxiliary diagnosis of renal cell carcinoma [2] - The cancer embryonic antigen (CEA) test mentioned by Ms. Zhang is not acknowledged as a reliable indicator for assessing the risk of renal cell carcinoma [2]